Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy duo aims to outdo chemo for common lymphoma

NCT ID NCT07634471

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 13 times

Summary

This large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated follicular lymphoma will take part. The study will check safety, how well the cancer responds, and whether the new combination helps people live longer without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-1045 (immunotherapy) combined with rituximab (targeted therapy)
What this could lead to
If successful, this could offer a more effective, chemotherapy-free first-line treatment for follicular lymphoma, potentially improving remission rates and delaying disease progression.
What could go wrong
This is an early-to-mid-stage trial (phase 2/3) with 960 participants. The experimental combination may not prove superior to standard chemo, and side effects from immunotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Chang Gung Medical Foundation-Linkou Branch ( Site 1002)

    RECRUITING

    Taoyuan, 333, Taiwan

  • Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Hacettepe Universite Hastaneleri ( Site 1110)

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Hadassah Medical Center ( Site 0701)

    RECRUITING

    Jerusalem, 9112001, Israel

  • Hospital Universitari Vall de Hebron ( Site 0903)

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario Gregorio Maranon ( Site 0902)

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Universitario de Salamanca ( Site 0906)

    RECRUITING

    Salamanca, 37007, Spain

  • Hospital Virgen de la Victoria ( Site 0905)

    RECRUITING

    Málaga, Malaga, 29010, Spain

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Instituto Alexander Fleming ( Site 0105)

    RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina

  • National Taiwan University Hospital ( Site 1001)

    RECRUITING

    Taipei, 10002, Taiwan

  • Ondokuz Mayıs Universitesi ( Site 1113)

    RECRUITING

    Samsun, 55270, Turkey (Türkiye)

  • SCRI Oncology Partners ( Site 7000)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sanatorio Nuestra Senora del Rosario ( Site 0104)

    RECRUITING

    Rosario, Santa Fe Province, S2001SBK, Argentina

  • Sheba Medical Center ( Site 0702)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Sisli Florence Nightingale Hastanesi ( Site 1112)

    RECRUITING

    Istanbul, 34381, Turkey (Türkiye)

  • Sourasky Medical Center ( Site 0704)

    RECRUITING

    Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.